About Emergent BioSolutions
Emergent BioSolutions is a company based in Gaithersburg (United States) founded in 1998. The company has 900 employees as of December 31, 2024. Emergent BioSolutions has completed 5 acquisitions, including ADAPT Pharma, Cangene and PaxVax. Emergent BioSolutions operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Gaithersburg, United States
- Employees 900 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Emergent Biosolutions Inc.
-
Annual Revenue
$1.04 B (USD)-0.54as on Dec 31, 2024
-
Net Profit
-$190.6 M (USD)74.94as on Dec 31, 2024
-
EBITDA
$53.6 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$384.96 K (USD), Grant
Sep 01, 2022
-
Investors
HHS
& 5 more
-
Employee Count
900
as on Dec 31, 2024
-
Investments & Acquisitions
ADAPT Pharma
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Emergent BioSolutions
Emergent BioSolutions is a publicly listed company on the NYSE with ticker symbol EBS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Emergent BioSolutions
Unlock access to complete
Unlock access to complete
Software Development Team
71 people
Leadership Team
60 people
Senior Team
23 people
Operations Team
19 people
Legal and Compliance
17 people
Finance and Accounting
15 people
Human Resources and Administration
13 people
Product Management Team
10 people
Unlock access to complete
Funding Insights of Emergent BioSolutions
Investors in Emergent BioSolutions
Emergent BioSolutions has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and Public Health Emergency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Global firm uses systematic strategies and machine learning for investment returns.
|
Locked | Locked | Locked |
Investor details for Emergent BioSolutions
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emergent BioSolutions
Emergent BioSolutions has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include ADAPT Pharma, Cangene and PaxVax.
Investment portfolio details for Emergent BioSolutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for emergency conditions are developed and reformulated.
|
Locked | Locked | 2014 | Locked | |
|
Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others.
|
Locked | Locked | 2007 | Locked | |
|
Antibody-like therapeutics for cancer and autoimmune diseases were developed.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Emergent BioSolutions
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Emergent BioSolutions
Detailed financials for Emergent BioSolutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emergent Biosolutions Comparisons
Peer comparison for Emergent BioSolutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emergent BioSolutions
Emergent BioSolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Detailed competitors of Emergent BioSolutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emergent Biosolutions
Complete news archive for Emergent BioSolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emergent BioSolutions
Emergent BioSolutions was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Emergent BioSolutions is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Robert G Kramer is the current CEO of Emergent BioSolutions.
As of Dec 31, 2024, the latest employee count at Emergent BioSolutions is 900.
Annual revenue of Emergent BioSolutions is $1.04B as on Dec 31, 2024.
Founded in 1998 and headquartered in Gaithersburg, United States, Emergent BioSolutions operates in the biotechnology sector with a focus on vaccine development for infectious diseases. Key products include NuThrax, a combination anthrax vaccine, PreviThrax in phase 1 trials for anthrax, VAX161C for pandemic influenza, and UV-4B, an antiviral for dengue in early trials. Contract manufacturing services are also provided for bulk drug substances and sterile injectables.
Emergent BioSolutions's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Yes, Emergent BioSolutions is publicly traded on NYSE under the ticker symbol EBS.
Emergent BioSolutions has made 5 acquisitions, including ADAPT Pharma, Cangene, and PaxVax.
Emergent BioSolutions has 6 investors. Key investors include HHS, European Union, Public Health Emergency, Aigen Investment Management, and National Institute on Drug Abuse.
The ticker symbol of Emergent BioSolutions is EBS on NYSE.